Tarik Asselah, MD, PhD

Tarik Asselah, MD, PhD, is professor of hepatology at the Hôpital Beaujon in Clichy, France, and at the University of Paris-Cité, and head of the unit Viral Hepatitis UMR1149 at INSERM.

Articles by Tarik Asselah, MD, PhD

Tarik Asselah, MD, PhD, screenshot on AJMC branded Q&A background

HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD

ByLaura Joszt, MA,Tarik Asselah, MD, PhD

June 16th 2026

Tarik Asselah, MD, PhD, explains why HDV RNA suppression deepened through 2 years with tobevibart plus elebsiran.

EASL Congress 2026 recap | Image credit: Mapics - stock.adobe.com

From EASL 2026: What Hepatology Still Needs to Solve

ByLaura Joszt, MA,Zobair Younossi, MD, MPH, FACG, FACP, AGAF,Mazen Noureddin, MD, MHSc,Tarik Asselah, MD, PhD,Meena Bansal, MD,Naim Alkhouri, MD

June 4th 2026

MASH cirrhosis treatment, fibrosis reversal, and population screening were cited by experts as hepatology's biggest gaps.

Screenshot of Tarik Asselah, MD, PhD, on AJMC branded background

Tobevibart-Elebsiran Sustains HDV Suppression at 96 Weeks: Tarik Asselah, MD, PhD

ByLaura Joszt, MA,Tarik Asselah, MD, PhD

May 29th 2026

Week 96 SOLSTICE data show tobevibart plus elebsiran deepens durable hepatitis D virus (HDV) and HBsAg suppression, beating monotherapy.

Tarik Asselah, MD, PhD

Articles by Tarik Asselah, MD, PhD

HDV Combo Shows No Relapses at 2 Years: Tarik Asselah, MD, PhD

From EASL 2026: What Hepatology Still Needs to Solve

Tobevibart-Elebsiran Sustains HDV Suppression at 96 Weeks: Tarik Asselah, MD, PhD

Latest Updated Articles

Trending on AJMC

FDA Approves First Oral Carbapenem Antibiotic for Complicated UTIs

Fourteen Years of HIV PrEP: How New Innovations Build on Decades of Progress in HIV

Oral COVID-19 PEP May Benefit High-Risk Groups More Than General Public: Peter J. Hotez, MD

Study Finds Flaw in Method for Key Oncology Value-Based Care Model

Ontada Analysis Finds GLP-1 RA Use Linked to Improved Survival in Patients With Cancer